| HOME >> MEDICINE >> TECHNOLOGY |
5.15.2 Revenue 102
5.15.3 Annual Cost of Treatment 106
5.15.4 Treatment Usage Patterns 107
5.16 Drivers and Restraints to Multiple Sclerosis Therapeutics Market 109
5.16.1 Drivers for Multiple Sclerosis Market 109
5.16.2 Restraints for Multiple Sclerosis Market 110
5.17 Parkinson's Disease 110
5.17.1 Introduction 110
5.17.2 Revenue 112
5.17.3 Annual Cost of Treatment 115
5.17.4 Treatment Usage Patterns 116
5.18 Drivers and Restraints to Parkinson's Disease Therapeutics Market 118
5.18.1 Drivers for the Parkinson's disease Therapeutics Market 118
5.18.2 Restraints for the Parkinson's disease Therapeutics Market 118
5.19 Schizophrenia 119
5.19.1 Introduction 119
5.19.2 Revenue 121
5.19.3 Annual Cost of Treatment 124
5.19.4 Treatment Usage Pattern 125
5.20 Drivers and Barriers to Schizophrenia Market 127
5.20.1 Drivers for Schizophrenia Market 127
5.20.2 Barriers for Schizophrenia Market 128
5.21 Major Depressive Disorder (MDD) 128
5.21.1 Introduction 128
5.21.2 Revenue 130
5.21.3 Annual Cost of Treatment 133
5.21.4 Treatment Usage Patterns 134
5.22 Drivers and Barriers to MDD Market 136
5.22.1 Drivers for MDD Market 136
5.22.2 Barriers for MDD Market 136
6 Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 138
6.1 Introduction 138
6.1.1 Product Pipeline by Indication 138
6.1.2 Product Pipeline by Clinical Stage of Development 139
6.2 Alzheimer's disease 140
6.2.1 Introduction 140
6.3 Attention Deficit Hyperactivity Disorder (ADHD) 150
6.3.1 Introduction 150
6.4 Bipolar Disorder 153
6.4.1 Introduction 153
6.5 Diabetic Neuropathy 155
6.5.1 Introduction 155
6.6 Epilepsy 157
6.6.1 Introduction 157
6.7 Insomnia 161
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |